Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 39M | 41M | 50M | 52M | 49M |
| Gross Profit | 20M | 24M | 30M | 32M | 31M |
| Operating Income | 11M | 14M | 17M | 20M | 19M |
| EBITDA | 17M | 16M | 25M | 27M | 26M |
| Net Income | 11M | 14M | 17M | 16M | 15M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$67.04
+2.04% today
1Y Change
+19.69%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Utah Medical Products, Inc. (UTMD) is a Healthcare stock with a market cap of $210.00M and listed on NASDAQ. The stock last traded around $67.04 and up 19.7% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -5.8%, EPS growth of -13.9%, a dividend yield of 1.9%. What stands out right now is revenue -5.8%, EPS -13.9%, free cash flow -1.9% with operating margin 28.8% and ROIC 7.2%. The dividend is present but secondary, with a yield around 1.9%. Valuation sits in the middle of the pack at P/E 19.3 and price/sales 5.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines UTMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
UTMD
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
UTMD Max Drawdown
-15.77%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for UTMD and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$49.1M
-6.2% YoY
FY Net Income
$14.8M
-10.2% YoY
Free Cash Flow
$20.7M
+1.6% YoY
Revenue Growth
-5.8%
EPS Growth
-13.9%
Gross Margin
53.6%
Net Margin
28.9%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 39M | 41M | 50M | 52M | 49M |
| Gross Profit | 20M | 24M | 30M | 32M | 31M |
| Operating Income | 11M | 14M | 17M | 20M | 19M |
| EBITDA | 17M | 16M | 25M | 27M | 26M |
| Net Income | 11M | 14M | 17M | 16M | 15M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 86M | 83M | 93M | 75M | 61M |
| Total Assets | 123M | 123M | 135M | 124M | 116M |
| Total Liabilities | 3M | 5M | 7M | 10M | 8M |
| Shareholder Equity | 119M | 117M | 128M | 114M | 107M |
| Total Debt | 225K | 338K | 295K | 341K | 396K |
| Net Debt | -86M | -83M | -93M | -75M | -61M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
21M
+0.3% YoY
Capital Expenditures
552K
+32.5% YoY
Free Cash Flow
21M
+1.6% YoY
Key ratios
Gross Margin
53.6%
Operating Margin
28.8%
Net Margin
28.9%
ROE
9.1%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.